Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial
| Autor: | Ingrid Choong, Jeffrey S. Glenn, Natasha Purington, Catherine Ley, Chaitan Khosla, Kent Y Feng, Yvonne Maldonado, Taia Wang, Manisha Desai, Prasanna Jagannathan, Ami S. Bhatt, Jason R. Andrews, Dean L. Winslow, Orlando Quintero, Savita Kamble, Hector Bonilla, Julie Parsonnet, Upinder Singh, Haley Hedlin, Karlie Edwards, Catherine A. Blish, Vidhya Balasubramanian, Jennifer A Newberry, Karen B. Jacobson, Colin Hislop, Christiaan R. de Vries, Benjamin A. Pinsky |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Adult Male medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Science Injections Subcutaneous Placebo-controlled study General Physics and Astronomy Placebo Gastroenterology Antiviral Agents General Biochemistry Genetics and Molecular Biology Article Transaminase Polyethylene Glycols 03 medical and health sciences Young Adult 0302 clinical medicine Internal medicine Outpatients medicine Clinical endpoint Humans Single-Blind Method 030212 general & internal medicine Treatment Failure Young adult Viral shedding Aged Multidisciplinary business.industry SARS-CoV-2 Interleukins Hazard ratio virus diseases COVID-19 General Chemistry Middle Aged Confidence interval Virus Shedding COVID-19 Drug Treatment 030104 developmental biology Viral infection Randomized controlled trials Female business |
| Zdroj: | Nature Communications Nature Communications, Vol 12, Iss 1, Pp 1-10 (2021) |
| ISSN: | 2041-1723 |
| Popis: | Type III interferons have been touted as promising therapeutics in outpatients with coronavirus disease 2019 (COVID-19). We conducted a randomized, single-blind, placebo-controlled trial (NCT04331899) in 120 outpatients with mild to moderate COVID-19 to determine whether a single, 180 mcg subcutaneous dose of Peginterferon Lambda-1a (Lambda) within 72 hours of diagnosis could shorten the duration of viral shedding (primary endpoint) or symptoms (secondary endpoint). In both the 60 patients receiving Lambda and 60 receiving placebo, the median time to cessation of viral shedding was 7 days (hazard ratio [HR] = 0.81; 95% confidence interval [CI] 0.56 to 1.19). Symptoms resolved in 8 and 9 days in Lambda and placebo, respectively, and symptom duration did not differ significantly between groups (HR 0.94; 95% CI 0.64 to 1.39). Both Lambda and placebo were well-tolerated, though liver transaminase elevations were more common in the Lambda vs. placebo arm (15/60 vs 5/60; p = 0.027). In this study, a single dose of subcutaneous Peginterferon Lambda-1a neither shortened the duration of SARS-CoV-2 viral shedding nor improved symptoms in outpatients with uncomplicated COVID-19. Here the authors report the results of randomized, single-blind, placebocontrolled trial on the effects of a asingle subcutaneous dose of Peginterferon Lambda-1a (Lambda) in 120 outpatients with mild to moderate COVID-19, showing that while treatment is well tolerated it does not shorten the duration of SARS-CoV-2 viral shedding nor improves symptoms. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|